Patents by Inventor Masaki Hirashima
Masaki Hirashima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11433160Abstract: A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer, and a laminated formed sheet product comprising a first polymer composition layer composed of fibrinogen and a water-soluble polymer and a second polymer composition layer composed of thrombin and an aliphatic polyester are provided. These formed products are applied onto a wound site and function as a hemostatic material.Type: GrantFiled: October 22, 2019Date of Patent: September 6, 2022Assignees: TEIJIN LIMITED, KM BIOLOGICS CO., LTD.Inventors: Yukako Kageyama, Kentaro Fujinaga, Ayuko Yamaguchi, Yusuke Akiyama, Akitoshi Oono, Susumu Honda, Makoto Satake, Hiroaki Kaneko, Takayuki Imamura, Ryoichi Kawamura, Masaki Hirashima
-
Patent number: 10774321Abstract: A method for monomerization of MMP-7 aggregates is provided. A method for monomerization of MMP-7 aggregates which comprises treating MMP-7 aggregates with a buffer solution comprising a monovalent cation chloride (sodium chloride, potassium chloride, etc.) at a low concentration or with a buffer solution not comprising a monovalent cation chloride, a process for preparing MMP-7 which involves said method for monomerization, and a (pharmaceutical) composition comprising MMP-7 in the aforementioned buffer solution. In case that a (pharmaceutical) composition comprising MMP-7 at a low concentration is prepared, the aforementioned buffer solution comprising sugar alcohols or sugars is used.Type: GrantFiled: May 20, 2015Date of Patent: September 15, 2020Assignee: KM BIOLOGICS CO., LTD.Inventors: Hiroshi Nakatake, Masaki Hirashima, Hideki Takeo, Reiko Matsuyama, Wataru Morikawa
-
Publication number: 20200140843Abstract: A method for monomerization of MMP-7 aggregates is provided. A method for monomerization of MMP-7 aggregates which comprises treating MMP-7 aggregates with a buffer solution comprising a monovalent cation chloride (sodium chloride, potassium chloride, etc.) at a low concentration or with a buffer solution not comprising a monovalent cation chloride, a process for preparing MMP-7 which involves said method for monomerization, and a (pharmaceutical) composition comprising MMP-7 in the aforementioned buffer solution. In case that a (pharmaceutical) composition comprising MMP-7 at a low concentration is prepared, the aforementioned buffer solution comprising sugar alcohols or sugars is used.Type: ApplicationFiled: January 14, 2020Publication date: May 7, 2020Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTEInventors: Hiroshi NAKATAKE, Masaki HIRASHIMA, Hideki TAKEO, Reiko MATSUYAMA, Wataru MORIKAWA
-
Publication number: 20200046877Abstract: A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer, and a laminated formed sheet product comprising a first polymer composition layer composed of fibrinogen and a water-soluble polymer and a second polymer composition layer composed of thrombin and an aliphatic polyester are provided. These formed products are applied onto a wound site and function as a hemostatic material.Type: ApplicationFiled: October 22, 2019Publication date: February 13, 2020Applicants: TEIJIN LIMITED, Teijin Pharma Limited, KM BIOLOGICS CO., LTD.Inventors: Yukako KAGEYAMA, Kentaro Fujinaga, Ayuko Yamaguchi, Yusuke Aklyama, Akitoshi Oono, Susumu Honda, Makoto Satake, Hiroaki Kaneko, Takayuki Imamura, Ryoichi Kawamura, Masaki Hirashima
-
Patent number: 10485894Abstract: A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer, and a laminated formed sheet product comprising a first polymer composition layer composed of fibrinogen and a water-soluble polymer and a second polymer composition layer composed of thrombin and an aliphatic polyester are provided. These formed products are applied onto a wound site and function as a hemostatic material.Type: GrantFiled: May 13, 2013Date of Patent: November 26, 2019Assignees: TEIJIN LIMITED, Teijin Pharma Limited, KM BIOLOGICS CO., LTD.Inventors: Yukako Kageyama, Kentaro Fujinaga, Ayuko Yamaguchi, Yusuke Akiyama, Akitoshi Oono, Susumu Honda, Makoto Satake, Hiroaki Kaneko, Takayuki Imamura, Ryoichi Kawamura, Masaki Hirashima
-
Publication number: 20170081654Abstract: A method for monomerization of MMP-7 aggregates is provided. A method for monomerization of MMP-7 aggregates which comprises treating MMP-7 aggregates with a buffer solution comprising a monovalent cation chloride (sodium chloride, potassium chloride, etc.) at a low concentration or with a buffer solution not comprising a monovalent cation chloride, a process for preparing MMP-7 which involves said method for monomerization, and a (pharmaceutical) composition comprising MMP-7 in the aforementioned buffer solution. In case that a (pharmaceutical) composition comprising MMP-7 at a low concentration is prepared, the aforementioned buffer solution comprising sugar alcohols or sugars is used.Type: ApplicationFiled: May 20, 2015Publication date: March 23, 2017Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTEInventors: Hiroshi NAKATAKE, Masaki HIRASHIMA, Hideki TAKEO, Reiko MATSUYAMA, Wataru MORIKAWA
-
Patent number: 9175295Abstract: A modified transposon vector and a method for introducing a foreign gene into a cell are provided.Type: GrantFiled: July 4, 2006Date of Patent: November 3, 2015Assignee: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTEInventors: Kazuyoshi Kaminaka, Hiroaki Maeda, Masaki Hirashima, Ryoichi Kawamura, Junichi Matsuda, Takashi Kuwana
-
Publication number: 20150151020Abstract: A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer, and a laminated formed sheet product comprising a first polymer composition layer composed of fibrinogen and a water-soluble polymer and a second polymer composition layer composed of thrombin and an aliphatic polyester are provided. These formed products are applied onto a wound site and function as a hemostatic material.Type: ApplicationFiled: May 13, 2013Publication date: June 4, 2015Applicants: TEIJIN LIMITED, TEIJIN PHARMA LIMITED, THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTEInventors: Yukako Kageyama, Kentaro Fujinaga, Ayuko Yamaguchi, Yusuke Akiyama, Akitoshi Oono, Susumu Honda, Makoto Satake, Hiroaki Kaneko, Takayuki Imamura, Ryoichi Kawamura, Masaki Hirashima
-
Publication number: 20150132279Abstract: A protein composition which comprises a mixture of glycine, phenylalanine and histidine and/or a cellulose ether derivative as an additive and has resistance to radiation sterilization.Type: ApplicationFiled: May 13, 2013Publication date: May 14, 2015Applicants: TEIJIN LIMITED, THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE, TEIJIN PHARMA LIMITEDInventors: Yukako Kageyama, Kentaro Fujinaga, Ayuko Yamaguchi, Yusuke Akiyama, Souichirou Katou, Yukiko Kimura, Susumu Honda, Makoto Satake, Hiroaki Kaneko, Ayumi Ishiwari, Masaki Hirashima
-
Patent number: 8748132Abstract: A process for preparing an inclusion body-forming protein is provided. A nucleic acid fragment having a nucleotide sequence coding for a modified alkaline phosphatase signal peptide (modified APSP) where leucine at the 13th position in the amino acid sequence shown in SEQ ID NO: 1 is substituted with proline and/or alanine at the 21st position is substituted with the other amino acid, downstream of which nucleotide sequence is bound a nucleotide sequence of a gene of a protein of interest is also provided.Type: GrantFiled: October 21, 2009Date of Patent: June 10, 2014Assignees: The Chemo-Sero-Therapeutic Research Institute, Teijin Pharma LimitedInventors: Hiroshi Nakatake, Akihiro Meta, Kiyotaka Suenaga, Masaki Hirashima, Hiroaki Maeda
-
Patent number: 8569238Abstract: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.Type: GrantFiled: March 18, 2013Date of Patent: October 29, 2013Assignees: The Chemo-Sero-Therapeutic Research Institute, Ginkyo Academy Kumamoto Health Science University, National University Corporation Kumamoto UniversityInventors: Shintaro Kamei, Asami Shindome, Takayoshi Hamamoto, Hiroaki Maeda, Masaki Hirashima, Sachio Okuda, Misako Umehashi, Sachie Ogawa, Megumi Imuta, Norio Akaike, Kazuo Takahama, Ryoko Wada
-
Publication number: 20130224179Abstract: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.Type: ApplicationFiled: March 18, 2013Publication date: August 29, 2013Inventors: SHINTARO KAMEI, ASAMI SHINDOME, TAKAYOSHI HAMAMOTO, HIROAKI MAEDA, MASAKI HIRASHIMA, SACHIO OKUDA, MISAKO UMEHASHI, SACHIE OGAWA, MEGUMI IMUTA, NORIO AKAIKE, KAZUO TAKAHAMA, RYOKO WADA
-
Publication number: 20120225818Abstract: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.Type: ApplicationFiled: August 5, 2010Publication date: September 6, 2012Applicants: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, GINKYO ACADEMY KUMAMOTO HEALTH SCIENCE UNIVERSITYInventors: Shintaro Kamei, Asami Shindome, Takayoshi Hamamoto, Hiroaki Maeda, Masaki Hirashima, Sachio Okuda, Misako Umehashi, Sachie Ogawa, Megumi Imuta, Norio Akaike, Kazuo Takahama, Ryoko Wada
-
Patent number: 8088624Abstract: A method of detecting thrombosis or the degree of thrombophilia by measuring a von Willebrand factor cleaving protease, and a kit for detecting thrombosis or the degree of thrombophilia, comprising an antibody or a fragment thereof specifically binding to a von Willebrand factor-cleaving protease, are disclosed. The detection method and the detection kit have an excellent convenience, rapidity, and specificity.Type: GrantFiled: December 22, 2004Date of Patent: January 3, 2012Assignee: Mitsubishi Kagaku Iatron, Inc.Inventors: Tomoko Ono, Kenji Soejima, Masaki Hirashima, Wataru Morikawa, Yoichi Sakata
-
Publication number: 20110262998Abstract: A process for preparing an inclusion body-forming protein is provided.Type: ApplicationFiled: October 21, 2009Publication date: October 27, 2011Applicants: TEIJIN PHARMA LIMITED, THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTEInventors: Hiroshi Nakatake, Akihiro Meta, Kiyotaka Suenaga, Masaki Hirashima, Hiroaki Maeda
-
Publication number: 20110183911Abstract: A novel medicament for ameliorating neurotransmission dysfunction diseases is provided. A medicament for ameliorating neurotransmission dysfunction diseases comprising as a main active ingredient preferably a selenocysteine-containing protein such as Selenoprotein P or a selenocysteine-containing peptide that consists of said protein or a series of said peptides. A medicament suited for ameliorating neurotransmission dysfunction diseases caused by various pathological conditions is provided.Type: ApplicationFiled: January 24, 2011Publication date: July 28, 2011Applicant: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTTITUTEInventors: Ryoichi Kawamura, Takeshi Naruse, Masaki Hirashima, Kazuyoshi Kaminaka, Junichi Matsuda, Hiroaki Maeda, Mami Noda, Keiji Wada
-
Patent number: 7960508Abstract: A peptide fragment or a series of peptide fragments containing one or more selenocysteine that has a lowered toxicity than selenocystine and that exhibits a cytotoxicity-inhibitory activity. The peptide fragment or a series of peptide fragments according to the present invention has preferably the amino acid sequence from 260th to 362nd amino acid residues from the C-terminal of selenoprotein P, or said amino acid sequence with one or several amino acid residues therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences. A screening method for a peptide fragment having the cytotoxicity-inhibitory activity is also provided.Type: GrantFiled: May 10, 2002Date of Patent: June 14, 2011Assignees: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Hisamitsu Pharmaceutical Co., Inc.Inventors: Masaki Hirashima, Takeshi Naruse, Hiroaki Maeda, Chikateru Nozaki, Takeshi Goto, Katsuhiko Akiyama, Wataru Hattori
-
Publication number: 20100281551Abstract: A modified transposon vector and a method for introducing a foreign gene into a cell are provided.Type: ApplicationFiled: July 4, 2006Publication date: November 4, 2010Inventors: Kazuyoshi Kaminaka, Hiroaki Maeda, Masaki Hirashima, Ryoichi Kawamura, Junichi Matsuda, Takashi Kuwana
-
Publication number: 20100113338Abstract: Disclosed is a novel composition for the treatment of a corneal/conjunctival disease. A prophylactic or therapeutic agent for a corneal/conjunctival disease comprising selenoprotein P as an active ingredient, more specifically a prophylactic or therapeutic agent for a corneal/conjunctival disease such as dry eye, keratoconjunctivitis sicca, superficial punctate keratopathy, corneal erosion or corneal ulcer comprising selenoprotein P as an active ingredient, particularly a prophylactic or therapeutic agent for a corneal/conjuncrtival disease such as dry eye, keratoconjunctivitis sicca, superficial punctate keratopathy, corneal erosion or corneal ulcer accompanied by a corneal/conjunctival epithelial discorder.Type: ApplicationFiled: June 21, 2006Publication date: May 6, 2010Applicants: KOWA COMPANY, LTD., Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Masanao Watanabe, Kazuo Tsubota, Masaki Hirashima, Chikateru Nozaki
-
Patent number: 7704951Abstract: A novel medicament for treating neurodegenerative diseases, especially for ameliorating dyskinesia, comprising as an active ingredient selenoprotein P and/or a peptide fragment or a series of peptide fragments derived from said protein is provided. The novel medicament for treating neurodegenerative diseases, especially for ameliorating dyskinesia, according to the present invention is suitably applicable to diseases with decrease in motor function.Type: GrantFiled: April 24, 2008Date of Patent: April 27, 2010Assignee: Juridical Foundation the Chemo-Sero-Therapeutic Research InstituteInventors: Masaki Hirashima, Takumi Sasaki, Takeshi Naruse, Hiroaki Maeda, Chikateru Nozaki